RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Quanzhou First Hospital, Fujian Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorQuanzhou First Hospital, Fujian Medical University福建医科大学附属泉州第一医院QuanzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07944313, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 60 years to 90 years; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07944313, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:① Non-small cell lung cancer (NSCLC) confirmed by histology or cytology; or cases that have not yet undergone pathological confirmation but simultaneously meet all of the following criteria: (a) Chest CT demonstrates a peripheral solid nodule or mass with clear malignant imaging features (lobulation, spiculation, pleural retraction, post-contrast enhancement); (b) 18F-FDG PET/CT shows lesion uptake higher than that of the mediastinal blood pool, with no distant metastases or mediastinal/hilar lymphadenopathy on whole-body imaging; (c) Previous imaging confirms lesion enlargement, or the doubling time is consistent with malignancy; (d) After discussion by the lung cancer MDT, it is unanimously concluded that the likelihood of primary peripheral lung cancer is extremely high, and small cell lung cancer, pulmonary metastases, and other benign lesions have been excluded; (e) The patient is unsuitable for or unwilling to undergo biopsy due to poor cardiopulmonary functional reserve, multiple comorbidities, high puncture risk, or explicit refusal; (f) The clinical diagnostic process and conclusion are fully documented in the medical record and the study CRF. ② Peripheral tumors with a maximum diameter ≤3 cm and a stage of T1N0M0 (8th edition TNM, IA1-IA3); those with invasion of the visceral pleura or atelectasis classified as T2aN0M0 (IB) may also be eligible for inclusion. ③ At enrollment, whether the diagnosis was "histologically/cytologically confirmed" is recorded (Yes/No) as a prespecified subgroup and sensitivity analysis factor (SAP), as predefined. ④ After enrollment, if pathology is obtained and confirms that the case is not NSCLC (e.g., small cell lung cancer), the patient will be withdrawn from the study treatment and receive standard treatment based on the actual pathology; such cases will be counted as protocol violations and included in the sensitivity analysis. ⑤ Age ≥75 years, or age <75 years but meeting any of the following criteria: CCI ≥3, ECOG 2-3, positive G8 screening, or CFS ≥4 on the Clinical Frailty Scale; ⑥ assessed by thoracic surgery as unsuitable for surgery, or deemed operable but explicitly declined surgery by the patient (an MDT record must be retained); ⑦ ECOG 0-3; ⑧ expected survival ≥12 months; ⑨ signed informed consent Exclusion Criteria:① Central or supercentral tumors (single-dose fractionation is not applicable); ② Previous history of thoracic radiotherapy; ③ Active infection in the ipsilateral lung or mediastinum; ④ Severe interstitial lung disease (requiring oxygen therapy or FVC/DLCO <35% of predicted value); ⑤ Patients requiring anticoagulation who cannot discontinue treatment due to a high risk of bleeding; ⑥ Presence of other malignant tumors within the preceding 5 years (excluding cured non-melanoma skin cancer and carcinoma in situ); ⑦ Patients who are unable to complete the 12-month follow-up or the PRO questionnaire; ⑧ Patients deemed unsuitable for enrollment by the investigator.

Quoted from ClinicalTrials.gov, NCT07944313, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07944313, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07944313